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Key messages
What is already known about this subject?
 ► Rituximab induces deep depletion of the B 
cells, but up to 35% of treated patients with 
rheumatoid arthritis (RA) do not achieve clinical 
European League Against Rheumatism response 
(Randomized Evaluation of Long-Term Efficacy 
of Rituximab in RA (REFLEX) trial).
 ► Prediction of response to this treatment remains 
challenging.
What does this study add?
 ► By analysing for the first time the B cell 
receptor (BCR) repertoire in peripheral blood 
and synovial tissue samples of patients with 
RA before and at different time points after 
treatment with rituximab, we provide new 
insight into the spatial and temporal effects of 
this drug on the B cell compartment.
 ► We observed major changes in BCR clonality at 
4 weeks after treatment, while the same effects 
are observed in synovial tissue only at later time 
points.
 ► We found a correlation between incomplete 
depletion of the pretreatment BCR repertoire 
in peripheral blood after 1 month of treatment 
and worse treatment response evaluated at 3 
months after treatment.
How might this impact on clinical practice or 
future developments?
 ► The early identification of non-responder 
patients based on early BCR clonality changes 
would allow clinicians to timely switch patients 
who are unlikely to respond to rituximab 
treatment to other therapies.
AbsTRACT
Objective To gain more insight into the dynamics of 
lymphocyte depletion and develop new predictors of 
clinical response to rituximab in rheumatoid arthritis 
(ra).
Methods rna-based next-generation sequencing was 
used to analyse the B cell receptor (Bcr) repertoire in 
peripheral blood and synovial tissue samples collected 
from 24 seropositive patients with ra treated with 
rituximab. clonal expansion, mutation load and clonal 
overlap were assessed in samples collected before, 
at week 4 and at week 16 or 24 after treatment and 
correlated to the patients’ clinical response.
Results after 4 weeks of rituximab-induced B cell 
depletion, the peripheral blood Bcr repertoire of 
treated patients consisted of fewer, more dominant 
and more mutated Bcr clones. no significant changes 
in the synovial tissue Bcr repertoire were detected 
until week 16 post-treatment, when a reduced clonal 
overlap with baseline and an increased mutation load 
were observed. in patients who were non-responders 
at month 3 (n=5) using the european league against 
rheumatism response criteria, peripheral blood samples 
taken at week 4 after rituximab treatment showed more 
dominant clones compared with moderate responders 
(n=9) (median (iQr): 36 (27–52) vs 18 (16–26); p<0.01) 
and more clonal overlap with the baseline (median (iQr): 
5% (2%–20%) vs 0% (0%–0%); p≤0.01).
Conclusion significant changes in Bcr clonality are 
observed in peripheral blood of patients 4 weeks after 
rituximab treatment, while changes in synovial tissue 
were observed at later time points. incomplete depletion 
of the dominant baseline peripheral blood Bcr repertoire 
in the first month of treatment might predict clinical non-
response at 3 months.
InTROduCTIOn
Rheumatoid arthritis (RA) is a chronic autoim-
mune disease that affects 1% of the population 
worldwide. The disease aetiology is not completely 
understood, and current treatments have limited 
efficacy.1 2 Currently, patients are treated long 
term with immunosuppressive therapies to control 
inflammation associated with pain, disability and 
joint destruction if left untreated. Understanding 
the mechanism underlying effective drug treatment 
may help to improve the response to therapy.
During the last decades, the introduction of 
biologicals constituted a major step forward in the 
treatment of RA. From a research perspective, the 
use of targeted therapies offers the opportunity 
to study the changes in the immune system while 
one cellular or molecular component is temporary 
depleted from the system. Rituximab, a chimeric 
monoclonal antibody directed against the B cell 
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a targeted therapy. A single treatment with rituximab induces 
>98% depletion of the B cells in peripheral blood lasting for 
at least 4–5 months, but clinical response is achieved in only 
50%–65% of treated patients.3 4
The exact mechanism by which depletion of CD20-bearing B 
cells leads to clinical improvement is still unclear.5 Incomplete 
B cell depletion in peripheral blood after rituximab treatment 
was initially considered the likely explanation for treatment 
failure.6–8 This notion is supported by the observation that 
high-sensitivity flow cytometry analyses could still detect class-
switched memory B cells and plasma cell precursors in peripheral 
blood in more than half of the patients after the first rituximab 
infusion.9 However, a clear correlation between the degree of 
B cell depletion in the peripheral blood and clinical response 
was not convincingly demonstrated.10 A second hypothesis to 
explain treatment failure is that this drug does not deplete all 
relevant B cell subsets, in particular in the tissues where B lineage 
cells may be protected against undergoing cell death.4 It has been 
consistently shown that B lineage cells may be protected from 
rituximab-induced depletion in the tissues, including synovial 
tissue and bone marrow.11 12 Of interest, there is a significant 
relationship between changes in B cell-derived plasma cells in 
the synovium and subsequent clinical response.12
Studies have been limited so far to the use of phenotypic 
cell markers. The development of RNA-based next-genera-
tion sequencing allowed us for the first time to analyse the B 
cell receptor (BCR) repertoire in different body compartments 
before and at different time points after rituximab treatment. 
The results presented here provide new insights into the effects 
of rituximab in peripheral blood and synovial tissue over time, 
and may help to identify new biomarkers predictive of response 




Twenty-four patients with active, IgM-rheumatoid factor and/
or anti-cyclic citrullinated peptides 2 test (CCP2)-positive RA13 
were included in this study. Study inclusion criteria, patient 
characteristics and clinical trial design have been described 
extensively before.12 14 The baseline characteristics of patients 
are reported in online supplementary table S1. The treatment 
protocol consisted of two intravenous injections of 1000 mg 
rituximab (Roche, Woerden, The Netherlands) on days 1 and 
15. Premedication with methylprednisolone was not allowed 
since it could have confounded the study, but stable metho-
trexate, prednisone and non-steroidal anti-inflammatory drugs 
were allowed. Patients were assessed for disease activity using 
the Disease Activity Score 28 joints.
samples
Peripheral blood and synovial tissue samples were collected 
before treatment (baseline (FU0)), at week 4 (follow-up 1 (FU1)) 
and at week 16 (follow-up 2 (FU2)) after rituximab treatment, as 
described before.12 14 For some patients the week 16 post-treat-
ment peripheral blood sample was not available and periph-
eral blood samples collected at week 24 were analysed instead. 
Peripheral blood mononuclear cells (PBMCs) were isolated from 
total blood using Ficoll separation (GE Healthcare, ref 17-1440-
02) and cryopreserved in liquid nitrogen until RNA isolation. 
Synovial tissue biopsies were collected by needle arthroscopy 
as previously described15 from an inflamed knee as judged by 
the treating physician and cryopreserved in liquid nitrogen until 
RNA isolation.
Linear amplification and next-generation sequencing of bCR 
repertoires
Starting material for RNA extraction consisted of 10 million 
PBMCs for peripheral blood samples and homogenised syno-
vial tissue biopsies for synovial tissue samples. RNA extraction, 
complementary DNA synthesis and quantitative amplification 
of BCR heavy chain molecules were performed as previously 
described.16–18 Information on the number of total and unique 
obtained sequences is reported in online supplementary table 
S2. Data sets were equalised to the minimum number of reads 
retrieved per tissue origin (2462 reads for peripheral blood 
samples, 2558 for synovial tissue samples). Sequences with 
100% CDR3 identity at the amino acid level were regarded as 
a ‘BCR clone’, and the frequency of each BCR clone was calcu-
lated as the number of identical sequences divided by the total 
sequences retrieved in each sample. BCR clones with a frequency 
above 0.5% were termed ‘dominant clones’. Additional analysis 
on the reproducibility of our approach and impact of sequencing 
depth on the quantification of dominant clones is reported in 
online supplementary figures S2 and S3.
statistics
Data are presented as mean and SD or median and IQR after 
D’Agostino and Pearson omnibus test for normality. Differences 
between groups were evaluated using Mann-Whitney U test for 
unpaired data, one-way analysis of variance or Kruskal-Wallis 
test of ranks data; p values less than 0.05 were considered statis-
tically significant. Prism V.7 software (GraphPad, San Diego, 
California) and RStudio (R V.3.3.2) were used to perform the 
analysis.
ResuLTs
Rituximab treatment induces clonality changes of the bCR 
repertoire in peripheral blood but not in synovial tissue
Following rituximab infusion there was deep depletion of 
CD19+ B cells in peripheral blood.12 As a first step we therefore 
tested whether our RNA-based technology was sensitive enough 
to detect the BCR repertoire in B cell-depleted peripheral blood 
samples. In all patients analysed, we were able to detect the 
BCR repertoire of both post-treatment peripheral blood samples 
(week 4 and week 16/24; online supplementary figure S1).
Next, we evaluated the effects of rituximab treatment on the 
BCR repertoire in both peripheral blood and synovial tissue. To 
this end we compared the number of BCR clones and the number 
of dominant BCR clones (clonal frequency >0.5% of the total 
repertoire) in samples collected before and after therapy. The 
number of BCR clones in the peripheral blood repertoire was 
significantly decreased after rituximab treatment compared with 
pretreatment conditions (median (IQR): FU0: 1738 (1476–
2095); FU1: 141 (105–206); FU2: 206 (131.0–379); p<0.0001), 
while the number of dominant BCR clones was significantly 
increased (median (IQR): FU0: 3 (2–9); FU1: 24 (17–33); FU2: 
28 (13–45); p<0.0001) (figure 1A,B). In contrast, there were 
no significant changes in the number of BCR clones or in the 
number of dominant BCR clones in the synovium at the different 
time points after treatment (figure 1C,D). Taken together these 
data indicate that rituximab drastically changes the peripheral 
blood BCR repertoire clonality while this was not observed in 
the BCR repertoire in the synovial tissue samples from the same 










is: first published as 10.1136/annrheum
dis-2018-214898 on 19 June 2019. Downloaded from
 
1341Pollastro S, et al. Ann Rheum Dis 2019;78:1339–1345. doi:10.1136/annrheumdis-2018-214898
Rheumatoid arthritis
Figure 1 Peripheral blood and synovial tissue BCR repertoire clonality during rituximab treatment. (A–B) Boxplots showing the number of total 
BCR clones and the number of dominant BCR clones (clonal frequency >0.5%) in the peripheral blood repertoire before (FU0=baseline) and after 
(FU1=week 4; FU2=week 16/24) treatment with rituximab. (C–D) Boxplots showing the number of BCR clones and the number of dominant BCR 
clones (clonal frequency >0.5%) in the synovial tissue repertoire before (FU0=baseline) and after (FU1=week 4; FU2=week 16/24) treatment 
with rituximab. Boxplots show the median and 25th and 75th interquartile, error bars show the range, and single data points are depicted in grey 
(****p≤0.0001 using two-way analysis of variance). BCR, B cell receptor.
The postdepletion bCR repertoire is mainly composed of 
highly mutated bCR clones
The phenotypic characterisation of the postdepletion B cell 
compartment using conventional flow cytometry is hindered by 
the small number of cells that can be detected, but high-sensitivity 
flow cytometry did allow detection of rituximab-residual B cells 
in peripheral blood.9 To gain more insight into the phenotypic 
composition of the postdepletion BCR repertoire, we analysed 
the mutation load in the BCR variable heavy (immunoglobulin 
heavy chain variable (IGHV)) genes as an indication of the matu-
ration status of the total BCR repertoire. A high mutation load 
indicates that the repertoire is dominated by mature BCR clones 
(ie, memory and plasma blasts/cells), while a low mutation load 
indicates that the BCR repertoire is mainly composed of imma-
ture BCR clones (ie, naïve). When we compared the mutation 
load (expressed as mutations/base pairs (bp)) in the peripheral 
blood repertoire of samples collected before and after ritux-
imab treatment, we found that the posttreatment repertoire had 
a significantly higher mutation load at both time points after 
treatment compared with the pretreatment repertoire (median 
(IQR): FU0: 0.012 (0.006–0.018); FU1: 0.056 (0.039–0.066); 
FU2: 0.055 (0.038–0.058); p<0.0001). In synovial tissue, there 
was a higher mutation load compared with peripheral blood 
before treatment. We could demonstrate a further increase in 
the mutation load in the synovial tissue samples taken 16 weeks 
after treatment (median (IQR): FU0: 0.043 (0.035–0.054); FU1: 
0.045 (0.038–0.051); FU2: 0.062 (0.052–0.062); p=0.0325) 
(figure 2A, C). We further characterised the phenotypic compo-
sition of the BCR repertoire before and after treatment by 
evaluating the fraction of repertoire composed of BCR clones 
with low (≤0.02 mutations/bp), medium (0.02–0.05 mutations/
bp) and high (≥0.05 mutations/bp) mutation load (figure 2B, 
D). The peripheral blood BCR repertoire before treatment is 
mainly composed of BCR clones with low mutation load (mean 
percentage 59%), while the highly mutated BCR clones domi-
nate the post-treatment repertoire at both time points analysed 
(mean percentage FU1: 57%; mean percentage FU2: 58%). 
In synovial tissue, however, medium and highly mutated BCR 
clones already dominate the repertoire before treatment (mean 
percentage medium: 39%; high: 45%), and a further increase in 
fraction of highly mutated BCR clones was observed in samples 
collected at 16 weeks after treatment (mean percentage FU2: 
60%). Collectively, these results indicate that the postdeple-
tion peripheral blood repertoire is mainly composed of highly 
mutated BCR clones. In addition, BCR clones with low mutation 
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Figure 2 Mutation analysis in peripheral blood and synovial tissue BCR repertoire during rituximab treatment. (A and C) Boxplots showing the 
mutation load (expressed as mutations/bp) in the peripheral blood (A) and synovial tissue (C) BCR repertoire before (FU0=baseline) and after 
(FU1=week 4; FU2=week 16/24) treatment with rituximab. Boxplots show the median and 25th and 75th interquartile, error bars show the range, and 
single data points are depicted in grey (*p≤0.05, ****p≤0.0001 using two-way analysis of variance). (B and D) Bar plots showing the distribution of 
BCR clones with low (≤0.02 mutations/bp, white bars), medium (0.02–0.05 mutations/bp, light grey bars) and high (≥0.05 mutations/bp, dark grey 
bars) mutation load in the peripheral blood (B) and synovial tissue (D) repertoire before (FU0=baseline) and after (FU1=week 4; FU2=week 16/24) 
treatment with rituximab. Bars’ height shows the median and error bars show the IQR. BCR, B cell receptor.
treatment, but it takes more time to see similar changes in syno-
vial tissue.
Rituximab treatment completely replaces the most dominant 
bCR clones in the repertoire
Compared with conventional cytometric techniques, BCR 
repertoire analysis offers the possibility to track individual BCR 
clones over time. Figure 3A shows an example of clonal overlap 
between the pretreatment BCR repertoire (FU0, x-axes) and 
the post-treatment BCR repertoires (FU1 and FU2, y-axes) of 
a rituximab-treated patient. The absence of shared BCR clones 
indicates that in this patient, all BCR clones present in peripheral 
blood prior to rituximab treatment cannot be retrieved in the 
post-treatment repertoires. To assess the qualitative changes in 
the BCR repertoire clonal composition induced by rituximab, we 
performed the clonal overlap analysis of the pretreatment and 
post-treatment BCR repertoires described above for all patients 
studied. The percentage of the overlapping top 50 clones (ie, 
how many identical BCR clones were shared within the 50 most 
dominant clones of the two repertoires in the comparison) was 
determined. Extremely low top 50 clonal overlap with the base-
line repertoire was observed in peripheral blood at both time 
points after treatment (median (IQR): FU0–FU1: 0% (0%–2%); 
FU0-FU2: 0% (0%–1.5%)) (figure 3C), indicating that in nearly 
all patients the BCR clones present in peripheral blood before 
treatment could not be detected in the post-treatment reper-
toires. In contrast, a higher top 50 clonal overlap was observed 
when comparing synovial tissue obtained 4 weeks after treatment 
with baseline samples, with a subsequent strong decrease in top 
50 clonal overlap 16 weeks after rituximab treatment (median 
(IQR): FU0–FU1: 8% (3%–20%); FU0–FU2: 5% (0%–11%)) 
(figure 3D). Together, these data show that rituximab treatment 
wipes out the dominant BCR clones from peripheral blood 
repertoire within the first 4 weeks of treatment and for up to 24 
weeks after treatment. In synovial tissue the BCR repertoire was 
unaltered 4 weeks after treatment, but the clonal overlap was 
clearly decreased 16 weeks after treatment.
Persistence of pretreatment dominant bCR clones in 
peripheral blood after 1 month of treatment associates with 
worse treatment response
Different biomarkers for response to rituximab have been 
proposed, but prediction of treatment response in the context 
of precision medicine remains a challenge.7 12 19 We therefore 
examined whether characteristics of the BCR repertoire before 
and after rituximab treatment could be predictive of treatment 
response. We analysed the differences between the baseline (FU0) 
and week 4 post-treatment (FU1) repertoire and correlated these 
to the patients’ clinical response evaluated 3 months after treat-
ment using the European League Against Rheumatism (EULAR) 
response criteria.20 Paired baseline and week 4 peripheral blood 
samples were available for a total of 14 patients, of whom 5 
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Figure 3 Clonal overlap in peripheral blood and synovial tissue BCR repertoire during treatment with rituximab. (A–B) Example of clonal overlap 
plots in the peripheral blood (A) and synovial tissue (B) BCR repertoire from one patient when comparing baseline with week 4 repertoire (black dots) 
or baseline with week 16 repertoire (red stars). Each symbol represents a unique BCR clone, and its frequency in the analysed repertoire is depicted 
on the x (baseline) and y (follow-up time point) axes as percentage of total reads. The red dotted lines indicate the 0.5% cut-off for dominant BCR 
clones, and the black dotted line indicates the plot diagonal. (C–D) Boxplot showing the clonal overlap within the top 50 clones of the pretreatment 
(FU0=baseline) and the post-treatment (FU1=week 4; FU2=week 16/24) BCR repertoires in peripheral blood (C) and synovial tissue (D). Boxplots 
show the median and 25th and 75th interquartile, error bars show the range, and single data points are depicted in grey. BCR, B cell receptor; N.D. not 
detected.
was a EULAR good responder at month 3.12 There were two 
predictors of non-response: first, non-responders at week 12 
had an increased number of dominant BCR clones in the periph-
eral blood repertoire 4 weeks after treatment (FU1) compared 
with moderate responders (median (IQR): moderate responders: 
18 (16–26); non-responders: 36 (27–52); p<0.01) (figure 4A). 
Second, non-responders showed a higher overlap of the top 50 
clones between the week 4 and baseline repertoires compared 
with moderate responders (moderate responders: 0% (0%–0%); 
non-responders: 5% (2%–20%); p=0.0091) (figure 4B). Taken 
together, these findings indicate that persistence of the baseline 
repertoire after 4 weeks of rituximab treatment is associated 
with subsequent non-response.
dIsCussIOn
In this experimental medicine study, we analysed the BCR reper-
toire to provide more insight into the effects of rituximab treatment 
on the peripheral blood and synovial tissue B cell compartments.
Our findings confirm and extend previous work showing 
that persistence of specific B cells is related to lack of clinical 
response to rituximab treatment in individual patients.9 Of 
interest, patients who do not achieve complete depletion of the 
BCR repertoire in peripheral blood within the first month of 
treatment do not achieve a clinical response after prolonged 
follow-up. These results indicate that early changes in peripheral 
blood could help to identify non-responders at an earlier time 
point, which would make it possible to switch patients who are 
unlikely to respond to rituximab treatment to other therapy.19 
These observations are in line with previous work showing that 
residual memory B cells and therefore pathogenic immunolog-
ical memory persists after rituximab treatment.9 21 This may help 
explain why a single course of rituximab, while clearly improving 
disease activity on the group level, does not cure RA.3 22
In addition, our findings raise the intriguing question as to 
which mechanisms are involved in the persistence and recur-
rence of specific BCR clones in individual patients. Future work 
addressing this question may pave the way for novel therapeutic 
strategies aimed at deep B cell intervention, for instance through 
innovative combination therapies.23 Rituximab-resistant 
BCR clones in peripheral blood are associated with treatment 
failure, as shown here, and memory B cells are the predomi-
nant repopulating fraction in patients with early relapse after 
B cell recovery.8 24 Why BCR clones may be resistant to ritux-
imab treatment is not completely understood. Possible mecha-
nisms include the presence of CD20-negative BCR clones (eg, 
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Figure 4 Correlation between peripheral blood BCR repertoire characteristics and clinical response at 3 months. (A) Boxplots showing the 
number of dominant BCR clones (clonal frequency >0.5%) in the peripheral blood repertoire at 4 weeks (FU1=week 4) after rituximab treatment in 
moderate and non-responder patients evaluated at 3 months. (B) Boxplots showing the clonal overlap within the top 50 clones of the pretreatment 
(FU0=baseline) and the first post-treatment (FU1=week 4) peripheral blood BCR repertoires in moderate and non-responder patients evaluated at 3 
months. Boxplots show the median and 25th and 75th interquartile, error bars show the range, and single data points are depicted in grey (**p≤0.01 
using Mann-Whitney test). BCR, B cell receptor; EULAR, European League Against Rheumatism.
prosurvival features or a relatively high influx of BCR clones 
into peripheral blood from the tissues where they are protected 
against cell death. The analysis of the BCR repertoire in synovial 
tissue based on the mutation load in the IGHV genes did indeed 
reveal the dominance of highly mutated BCR clones. This is in 
line with the notion that organised lymphoid aggregates, which 
contain mainly mature (and thus mutated) memory and plasma B 
cell subsets, are present in rheumatoid synovium.25 26 After ritux-
imab treatment, a further increase in the highly mutated clonal 
fraction in the synovial tissue BCR repertoire is most likely a 
consequence of the reduction of BCR clones with low muta-
tion load. This reduction could be attributed to a direct effect 
of rituximab on synovial tissue B cells, or could reflect reduced 
influx of immature B cells from the peripheral blood,18 27–29 a 
mechanism thought to be important in the perpetuation and in 
the onset of the clinical signs and symptoms of the disease.29
Our study has several weaknesses. First, the number of patients 
here analysed is low due to the requirement for repeated synovial 
biopsies. As a consequence, the observed correlation between early 
changes in peripheral BCR clonality and treatment outcome needs 
additional exploration to establish its test characteristics in larger 
cohorts with standard clinical practice. Furthermore, given the 
limited number of retrieved reads using the Roche platform, we 
focused on the dominant clones (>0.5% of the repertoire) since 
the sequence depth has only minor effects on their quantification 
(online supplementary figure S3). It should also be noted that our 
analysis is performed starting from RNA and should therefore be 
interpreted as a repertoire analysis of BCR clones, rather than an 
actual representation of the B cell repertoire on the DNA level. 
This is relevant when looking at the persisting, highly mutated 
clones on the RNA level that likely reflect (CD20-negative) plasma 
blasts and/or plasma cells. The presence of these cells is expected 
to increase the number of dominant clones, in line with our results. 
Although we did not detect B cells using conventional flow cytom-
etry, we do not exclude the possibility that part of the BCR signa-
tures does derive from B cells, which might be detectable by more 
sensitive flow cytometry techniques. Finally, our approach yields 
little information on the phenotype and specificity of the detected 
dominant BCR clones. Do these BCR clones encode rheumatoid 
factor and/or anticitrullinated protein specificity? In this context 
it would be of interest to investigate whether repertoire analysis 
also shows dominant BCR clones in seronegative patients with RA 
and whether the impact of rituximab on such dominant clones is 
identical.
In conclusion we have shown that in peripheral blood of RA 
patients, the postrituximab BCR repertoire is mainly composed 
of fewer but more dominant and more mutated BCR clones. In 
the synovial tissue, changes in BCR clonality are observed at 
later time points compared with peripheral blood, which could 
explain in part the relatively slow onset of clinical efficacy of 
rituximab treatment. Patients who do not respond to rituximab 
at 3 months show incomplete depletion of the baseline BCR 
clonal repertoire in peripheral blood within the first month of 
treatment, revealing a promising early predictive marker of clin-
ical response.
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